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Abstract
Introduction: The pharmacological management of osteoarthritis normally begins with the
administration of acetaminophen or a nonselective nonsteroidal anti-inflammatory drug. However,
acetaminophen may not be efficacious in all patients, and nonsteroidal anti-inflammatory drugs may
be associated with gastrointestinal and cardiovascular adverse effects.
Case presentation: A 79-year-old Caucasian man with bilateral hip pain was diagnosed with
osteoarthritis of the hip. His past medical history included three prior myocardial infarctions, the
most recent one occurring 2 years ago. He is taking aspirin 81 mg once daily. Despite no history of
ulcer disease or bleeding, he has been reluctant to take nonsteroidal anti-inflammatory drugs, and
because of his cardiac history there is a contraindication to cyclooxygenase-2-specific inhibitors. He
was started on naproxen 220 mg twice daily, with the proton pump inhibitor omeprazole 20 mg once
daily. Upon follow-up at 4 weeks, his hip pain had decreased from a rating of 7 (on a ten-point scale)
to 5 on his left side and from 5 to 2 on his right side. The patient began a course of physical therapy in
conjunction with a regimen of naproxen 440 mg in the morning and 220 mg at night, plus the
omeprazole and acetaminophen 650 mg twice daily. He reported no gastrointestinal effects.
Conclusion: The addition of a proton pump inhibitor to nonsteroidal anti-inflammatory drug
therapy can reduce the risk of peptic ulcer bleeding by ≥80%, making the incidence of gastropathy the
same as with cyclooxygenase-2-specific inhibitors. The fact that naproxen is not associated with an
increased risk of acute myocardial infarction made it an appropriate choice for this patient.
Introduction
Osteoarthritis (OA) is the most common joint disorder
in the United States and one of the leading causes of
disability in the elderly. Approximately 5% of the
population over the age of 65 years has radiographic
evidence of OA of the hip, and nearly 200,000 total hip
replacements are performed annually [1]. There is no cure
for OA, but many pharmacologic options exist for
managing its symptoms.
Case presentation
A 79-year-old Caucasian retired physician presented to the
office with a chief complaint of bilateral hip pain that had
been present for approximately 2 years but had become
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described the pain as dull and achy and located anteriorly
in both hips with occasional radiation to the groin. At its
most severe the pain was rated as a 7 on a ten-point scale
in theleft hip and asa 5 in theright hip. The painwas most
severe in the morning, when the patient first got out of
bed, and in the evening, after he had been active all day.
There was no history of trauma, and the patient denied
other joint symptoms. He reported that acetaminophen
650 mg two or three times daily had been effective for
managing his pain but no longer was. He tried ibuprofen
400 mg three times daily, and while it provided adequate
pain relief, he was reluctant to begin nonsteroidal anti-
inflammatory drug (NSAID) therapy for fear of gastro-
intestinal (GI) side effects. The patient had taken
tramadol, hydrocodone, and oxycodone in the past but
experienced troublesome lightheadedness.
The patient’s past medical history was significant for
coronary artery disease and three prior myocardial
infarctions (MIs), the most recent having been 2 years
earlier. He was told to take aspirin 81 mg once daily to
relieve his current pain. He denied any history of peptic
ulcer disease, upper GI bleeding or other bleeding
disorders, liver or kidney disease, chronic steroid use,
and excessive alcohol intake.
On physical examination, the patient was able to walk
without an assistive device but demonstrated a slightly
antalgic gait. Hip internal rotation was painful and limited
to 15° bilaterally. External rotation was 50° on the right
side and 40° on the left side. Hip flexion and extension
were within normal limits. Flexion-abduction-external
rotation (FABER) provocative testing produced hip pain
bilaterally. Results of a lower-extremity strength examina-
tion are indicated in Table 1. Sensation was intact to light
touch. Examination of the patient’s knees demonstrated
mild crepitus bilaterally, and results of a lumbar spinal
examination were unremarkable.
This patient met the American College of Rheumatology
clinical criteria for OA of the hip [2], which was hip pain
plus hip internal rotation of ≥15°, pain with hip internal
rotation, morning stiffness of the hip for ≤60 minutes, and
age >50 years or hip pain plus hip internal rotation of <15°
and erythrocyte sedimentation rate (ESR) of ≤45 mm/hr or
hip flexion of <115° if the ESR is not known.
Treatment
The patient was concerned about long-term NSAID
therapy because of potential GI side effects and was
reluctant to retry opioid therapy since he had previously
experienced lightheadedness. With the patient’s prior
history of MIs, cyclooxygenase (COX)-2-specific inhibitors
were ruled out as a potential therapy. After reviewing the
benefits and relative risk reduction of GI adverse events
provided when a proton pump inhibitor (PPI) is used in
combination with a nonselective NSAID, his physician
decided to start the patient on over-the-counter (OTC)
naproxen 220 mg every 12 hours in conjunction with the
PPI omeprazole 20 mg once daily. The patient was advised
of the black box warnings regarding naproxen that are
related to cardiovascular (CV) and GI adverse events [3],
as well as other possible side effects. He also advised the
patient to start a program of physical therapy and
instructed him to continue taking acetaminophen
650 mg up to four times per day as needed.
When the patient returned to the office 4 weeks later, the
patient hadbeen inaphysical therapy program for 3 weeks
and was taking naproxen 440 mg in the morning and
220 mg at night, omeprazole 20 mg once daily, and
acetaminophen 650 mg twice daily. He rated his pain on
this regimen as a 5 on a ten-point scale in the left hip and
a 2 in the right hip. He was given a straight cane by a
physical therapist, which he found to be very helpful in
alleviating some of his pain during walking. He reported
no adverse GI effects and was pleased with his treatment
and progress. He was able to tolerate physical therapy and
was learning a home exercise program. A follow-up visit
was scheduled for 2 months, during which time the
patient will have completed his course of physical therapy;
however, he will continue his home exercise program and
adhere to his medication regimen.
Discussion
While initial treatment for OA should include nonphar-
macologic intervention, when such therapy provides
insufficient pain relief, medications should be added
while the non-pharmacologic therapy is continued. After
careful assessment of risk factors and medical co-morbid-
ities, initial pharmacologic management should begin
with acetaminophen or a nonselective NSAID, such as
naproxen or ibuprofen. While the nonselective NSAIDs
should be used with caution because of their potential for
Table 1. Lower-Extremity Strength*
Hip Flexion Hip Extension Hip Abduction Hip Adduction Knee Extension Knee Flexion Ankle Dorsiflexion Ankle Plantarflexion
R 5/5 5/5 4/5 4+/5 5/5 5/5 5/5 5/5
L 5/5 5/5 4+/5 4+/5 5/5 5/5 5/5 5/5
*Graded on a scale of 1 to 5, where 1 represents minimal strength and 5 represents maximal strength.
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showed that the addition of a PPI to NSAID therapy
reduced the risk of peptic ulcer bleeding by 82% [4]. The
study also showed that patients taking a nonselective
NSAID and a PPI have the same incidence of NSAID-
induced gastropathy as patients taking a COX-2-specific
inhibitor. Currently, two fixed-dose combinations of
an NSAID and a PPI are in development; naproxen/
esomeprazole from AstraZeneca [5] and ibuprofen/
famotidine from Horizon Therapeutics [6]. While both
ibuprofen and naproxen are available in higher, pres-
cription-strength doses as well as lower, OTC doses, the
occurrence of adverse GI side effects in patients taking
OTC doses of naproxen (up to 660 mg/day) has been
shown to be comparable to, and in some cases lower than,
the incidence of GI side effects in patients taking placebo
[7]. Additionally, while COX-2-specific inhibitors have
been linked to an increased risk of CV events [8], naproxen
has been shown not to be associated with an increased risk
of acute MI [9,10].
Another important issue that arises when initiating
treatment for patients with OA who are already taking
aspirin for cardioprotection is that certain NSAIDs may
interfere with the antithrombotic benefits of aspirin
through a competitive interaction with platelet COX-1.
The co administration of ibuprofen and aspirin has been
shown to antagonize aspirin’s irreversible platelet inhibi-
tion, indicating that the use of ibuprofen in patients at
increased CV risk could limit the cardioprotective effects of
aspirin [11,12]. Post hoc analysis of the TARGET (Ther-
apeutic Arthritis Research and Gastrointestinal Event Trial)
study showed that among patients at high CV risk already
taking aspirin, the incidence of CV events was significantly
higher in the subgroup taking ibuprofen but not in the
subgroup taking naproxen when each was compared
with lumiracoxib [13]. The concomitant administration
of acetaminophen [11,14], or naproxen in prescription
[15],or nonprescription doses [11],has not beenshown to
reduce the COX-1-mediated platelet inhibition induced by
aspirin, suggesting that these two medications may be
safer choices in patients at higher CV risk who are receiving
aspirin therapy.
Conclusions
The application of clinical data to decision making is
critical in determining the optimal treatment regimen for
patients with OA. The use of OTC naproxen in association
with a PPI and low-dose aspirin was found to be effective
in treating OA of the hip in this patient with CV and GI risk
factors.
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